Serina Therapeutics, Inc.
SER · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $36,869 | $115,691 | $21,265 | $41,936 |
| - Cash | $3,672 | $345 | $532 | $315 |
| + Debt | $268 | $4,365 | $1,809 | $398 |
| Enterprise Value | $33,465 | $119,711 | $22,542 | $42,020 |
| Revenue | $56 | $3,153 | $500 | $3,039 |
| % Growth | -98.2% | 530.6% | -83.5% | – |
| Gross Profit | -$138 | $3,063 | $500 | $3,039 |
| % Margin | -246.4% | 97.1% | 100% | 100% |
| EBITDA | -$10,487 | $5,917 | -$2,605 | -$1,228 |
| % Margin | -18,726.8% | 187.7% | -521% | -40.4% |
| Net Income | -$11,141 | $5,269 | -$2,682 | -$1,265 |
| % Margin | -19,894.6% | 167.1% | -536.4% | -41.6% |
| EPS Diluted | -1.51 | 0.63 | -2.49 | -8.05 |
| % Growth | -339.7% | 125.3% | 69.1% | – |
| Operating Cash Flow | -$17,137 | -$2,476 | -$2,076 | -$2,251 |
| Capital Expenditures | -$22 | -$504 | -$10 | -$108 |
| Free Cash Flow | -$17,159 | -$2,980 | -$2,085 | -$2,359 |